WSJ: J&J consumer-health IPO process to kick off key test for moribund new-issue market
THE WALL STREET JOURNAL reports: Johnson & Johnson is poised to begin a roadshow to pitch ...
Barron’s writes:
Johnson & Johnson’s Covid-19 vaccine offers enormous promise as a pathway out of the worst of the pandemic. Delivered as a single dose, without the extreme storage requirements of the vaccines from Pfizer and Moderna, it could speed up global inoculation if it proves effective.
But on Wednesday, the New York Times reported that the company is facing delays in the manufacturing of the vaccine that have put it up to two months behind its initial production schedule. The report comes amid growing anticipation for data from Johnson ...
Comment on this article